Wolfe Research initiated coverage of Celcuity (CELC) with an Outperform rating and $110 price target Fresh off a Phase 3 win for gedatolisib in second-line PIK3CA-wt breast cancer, the firm sees additional upside as the PIK3CA-mt readout looks “primed to deliver next year,” the analyst tells investors. The firm views Celcuity as “a top-tier acquisition opportunity for big pharma,” the analyst added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELC:
- Block upgraded, Dell downgraded: Wall Street’s top analyst calls
- Celcuity downgraded to Neutral from Buy at H.C. Wainwright
- Celcuity’s Gedatolisib: A Promising Standard for 2L Breast Cancer Treatment
- Celcuity Inc. Earnings Call: Strong Progress Amid Challenges
- Celcuity price target raised to $108 from $96 at Craig-Hallum